Metagenomi Therapeutics, Inc.

Metagenomi Therapeutics, Inc. (MGX) priced its initial public offering on Feb 12, 2024 at $15.00 per share, within its $15.00–$17.00 range, raising $93.8M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $562.9M. J.P. Morgan was lead-left underwriter, joined by Jefferies, TD Cowen and Wells Fargo and others. Goodwin Procter advised the company and Davis Polk advised the underwriters.

Metagenomi Therapeutics, Inc. is a precision genetic medicines company developing curative therapeutics for genetic diseases. It builds on a genome editing toolbox derived from metagenomics, which includes programmable nucleases and base editors.

Status

IPO

Ticker

MGX

Exchange

Nasdaq Global Select

Priced

Feb 12, 2024

IPO price

$15.00

Price range

$15.00–$17.00

Raised

$93.8M

Market cap at IPO price

$562.9M

First filed

Jan 5, 2024

Underwriters

J.P. Morgan, Jefferies, TD Cowen, Wells Fargo, BMO Capital Markets and Chardan

Company counsel

Goodwin Procter

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.